Lipocine INC 8-K filings

Lipocine Inc. announced its second quarter 2026 financial results and provided a corporate update, highlighting a missed primary endpoint in its LPCN 1154 Phase 3 trial for postpartum depression.

Lipocine Inc. announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026, to enhance its strategic development and partnership efforts.

Lipocine Inc. conducted a virtual key opinion leader event to discuss the clinical profile of LPCN 1154 for treating postpartum depression.

Lipocine Inc. announced that shareholders approved amendments to its 2014 Stock and Incentive Plan, increasing award limits and authorized shares, and re-elected directors at the annual meeting.

Lipocine Inc. announced a virtual Key Opinion Leader event on June 12, 2026, to discuss unmet needs in postpartum depression and the clinical profile of its investigational drug LPCN 1154.

Lipocine Inc. presented Phase 3 clinical trial data for LPCN 1154, an oral brexanolone treatment for postpartum depression, at the ASCP Annual Meeting.

Lipocine Inc. announced that Phase 3 clinical data for its drug candidate LPCN 1154 has been selected for oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.

Lipocine Inc. announced its management will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Company Showcase on May 20, 2026.

Lipocine Inc. reported first quarter 2026 financial results and provided an update on its LPCN 1154 Phase 3 trial for postpartum depression, which did not meet its primary endpoint.

Lipocine Inc. announces the immediate resignation of its Chairman and Lead Independent Director, Spyros Papapetropoulos, citing strategic disagreements, with R. Dana Ono appointed as his successor.

Lipocine Inc. has filed an updated corporate presentation for use in investor and analyst communications.

Lipocine Inc. announced that its Phase 3 trial for LPCN 1154 in postpartum depression failed to meet its primary endpoint, though post hoc analysis showed promise in a specific patient subset.

Lipocine Inc. announced the filing of a prospectus supplement to offer and sell up to $50 million of common stock through an at-the-market offering.

Lipocine Inc. announced the completion of enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, an oral treatment for postpartum depression.

Lipocine Inc. announced it has updated and filed its corporate presentation for investor and analyst meetings.

Lipocine Inc. announced encouraging progress in its Phase 3 trial of LPCN 1154 for postpartum depression following a positive second interim safety review by the Data and Safety Monitoring Board.

Lipocine Inc. announced 80% enrollment completion for its Phase 3 clinical trial of LPCN 1154 for postpartum depression, with topline results expected in Q2 2026.

Jeffrey Fink will resign from Lipocine Inc.'s Board of Directors effective January 1, 2026, citing personal reasons.

Lipocine Inc. presented new clinical and toxicokinetic data for its epilepsy candidate, LPCN 2101, at the American Epilepsy Society Annual Meeting.

Lipocine Inc. filed an 8-K to announce an updated corporate presentation for investor and analyst meetings.

Lipocine Inc. announced promising interim safety results for its LPCN 1154 Phase 3 clinical trial for postpartum depression, with the study continuing as planned.

Lipocine Inc. announced its third-quarter 2025 financial and operational results, highlighting progress in its Phase 3 PPD trial and exploring partnerships for its drug candidates.

Lipocine Inc. announced positive 20-week Phase 2 clinical data for LPCN 2401, demonstrating rapid improvements in body composition and liver health in men with obesity.

Lipocine Inc. announced that its pivotal Phase 3 clinical trial for LPCN 1154 in Postpartum Depression is progressing on track, with one-third of patients randomized and topline results expected in Q2 2026.

Lipocine Inc. updated its corporate presentation to reflect a pause in the LPCN 2401 POC study while seeking regulatory clarity on development path and endpoints.

Lipocine Inc. announced its management will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference from September 8-10, 2025.

Lipocine Inc. announced its participation and presentation at the H.C. Wainwright 27th Annual Global Investor Conference in New York City from September 8-10, 2025.

Lipocine Inc. announced that two abstracts for its epilepsy treatment candidate, LPCN 2101, have been accepted for presentation at the 2025 American Epilepsy Society annual meeting.

Lipocine Inc. reported reduced Q2 2025 net loss, initiated Phase 3 for LPCN 1154 in PPD, and plans Phase 2 for LPCN 2401 in obesity, while expanding TLANDO's global reach.

Lipocine Inc. announced it hosted a virtual Key Opinion Leader (KOL) event to discuss LPCN 1154, branded as BRLIZIO, as a potential treatment for postpartum depression.